To further confirm that GCB-DLBCL cells with GNA13 mutations are hypersensitive to the treatment with BCL2 inhibitors, we compared the sensitivity of ABT-199 (also known as venetoclax, the third-generation BCL2 inhibitor41) in treating GCB-DLBCL cell lines either with the WT GNA13 (SU-DHL4) or mutant GNA13 (OCI-LY1). This evidence concerns the gene GNA13 and diffuse large B-cell lymphoma.